Mark L. Baum
2021
In 2021, Mark L. Baum earned a total compensation of $7.3M as Chief Executive Officer at Imprimis Pharmaceuticals, a 195% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $492,503 |
|---|---|
| Salary | $564,596 |
| Stock Awards | $6,251,841 |
| Other | $12,527 |
| Total | $7,321,467 |
Baum received $6.3M in stock awards, accounting for 85% of the total pay in 2021.
Baum also received $492.5K in non-equity incentive plan, $564.6K in salary and $12.5K in other compensation.
Rankings
In 2021, Mark L. Baum's compensation ranked 1,640th out of 12,415 executives tracked by ExecPay. In other words, Baum earned more than 86.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,640 out of 12,415 | 87th |
Division Manufacturing | 599 out of 5,501 | 89th |
Major group Chemicals And Allied Products | 224 out of 2,371 | 91st |
Industry group Drugs | 187 out of 2,092 | 91st |
Industry Pharmaceutical Preparations | 124 out of 1,542 | 92nd |
Source: SEC filing on April 26, 2022.
Baum's colleagues
We found two more compensation records of executives who worked with Mark L. Baum at Imprimis Pharmaceuticals in 2021.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019